Abstract
The seeding of amyloid-β 40 (Aβ40) oligomers from monomers is the initial step of Aβ aggregation, and many reports have suggested that cholesterol enhances this step. We studied the potential of secosteroid vitamin D derivatives for Aβ40 aggregation in vitro. The quartz-crystal microbalance technique demonstrated that vitamin D3 does not show any effect on Aβ40 aggregation while vitamin D2 promoted it and docking simulation but that vitamin D2 has high potential in this regard. Thus, stacking of the Phe19 benzene ring in Aβ40 and the C22-C23 double bond in vitamin D2 may alter the energy of these molecules. Electron microscopy revealed the potential of vitamin D2 to increase Aβ40 aggregation. Thioflavin-T assays indicated that Vitamin D2 induced increased fluorescence at 490 nm, as typically observed for amyloid fibrils but also for protofibrils; in both cases this reflects of the increase of β-sheet contents. Aβ40 aggregation was further confirmed in ELISA, SDS-PAGE and dot blot analysis which revealed changes in protease K resistance. These results suggest a possible mechanism, of how vitamin D2 could increase Aβ40 aggregation and the docking simulation explains, why the same is not observed with vitamin D3.
Keywords: Aggregation, Alzheimer's disease, amyloid-β, β-sheet formation, quartz-crystal microbalance technique, vitamin D derivatives.
Current Alzheimer Research
Title:Different Effect of Vitamin D2 and Vitamin D3 on Amyloid-β40 Aggregation In Vitro
Volume: 11 Issue: 8
Author(s): Midori Suenaga, Hironobu Takahashi, Hiroshi Imagawa, Michiru Wagatsuma, Shinji Ouma, Yoshio Tsuboi, Akiko Furuta and Yoichi Matsunaga
Affiliation:
Keywords: Aggregation, Alzheimer's disease, amyloid-β, β-sheet formation, quartz-crystal microbalance technique, vitamin D derivatives.
Abstract: The seeding of amyloid-β 40 (Aβ40) oligomers from monomers is the initial step of Aβ aggregation, and many reports have suggested that cholesterol enhances this step. We studied the potential of secosteroid vitamin D derivatives for Aβ40 aggregation in vitro. The quartz-crystal microbalance technique demonstrated that vitamin D3 does not show any effect on Aβ40 aggregation while vitamin D2 promoted it and docking simulation but that vitamin D2 has high potential in this regard. Thus, stacking of the Phe19 benzene ring in Aβ40 and the C22-C23 double bond in vitamin D2 may alter the energy of these molecules. Electron microscopy revealed the potential of vitamin D2 to increase Aβ40 aggregation. Thioflavin-T assays indicated that Vitamin D2 induced increased fluorescence at 490 nm, as typically observed for amyloid fibrils but also for protofibrils; in both cases this reflects of the increase of β-sheet contents. Aβ40 aggregation was further confirmed in ELISA, SDS-PAGE and dot blot analysis which revealed changes in protease K resistance. These results suggest a possible mechanism, of how vitamin D2 could increase Aβ40 aggregation and the docking simulation explains, why the same is not observed with vitamin D3.
Export Options
About this article
Cite this article as:
Suenaga Midori, Takahashi Hironobu, Imagawa Hiroshi, Wagatsuma Michiru, Ouma Shinji, Tsuboi Yoshio, Furuta Akiko and Matsunaga Yoichi, Different Effect of Vitamin D2 and Vitamin D3 on Amyloid-β40 Aggregation In Vitro, Current Alzheimer Research 2014; 11 (8) . https://dx.doi.org/10.2174/156720501108140910121139
DOI https://dx.doi.org/10.2174/156720501108140910121139 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Alzheimer's Disease Drug Development
Alzheimer's disease is a progressive neurodegenerative disorder that affects millions of people worldwide. Despite decades of research, no cure or disease-modifying treatment is available yet. Therefore, the need for developing effective therapies to treat Alzheimer's disease is an urgent matter. This special issue aims to provide a comprehensive overview of ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Ezetimibe and Reactive Oxygen Species
Current Vascular Pharmacology The Use of the Inhibitory Receptors for Modulating the Immune Responses
Current Pharmaceutical Design Lysosomal Molecules are Up-Regulated in the Articular Cartilage Explants Subjected to Oxidative Stress and in the Cartilage from an Osteoarthritis-Induced Rat Model
Recent Patents on Biomarkers Hypertension and Heart Failure with Preserved Ejection Fraction: Connecting the Dots
Current Vascular Pharmacology Heart Failure in South Asia
Current Cardiology Reviews Autonomic Nervous System in Viral Myocarditis: Pathophysiology and Therapy
Current Pharmaceutical Design NTproBNP: An Important Biomarker in Cardiac Diseases
Current Topics in Medicinal Chemistry A Review on Recent Patents in Digital Processing for Cardiac Electric Signals (II): Advanced Systems and Applications
Recent Patents on Biomedical Engineering (Discontinued) Protein Kinases and their Modulation in the Central Nervous System
Current Medicinal Chemistry - Central Nervous System Agents Adrenomedullin in Heart Failure: Molecular Mechanism and Therapeutic Implication
Current Hypertension Reviews Nitric Oxide and Protection against Cardiac Ischemia
Current Pharmaceutical Design Muscle Atrophy Classification: The Need for a Pathway-Driven Approach
Current Pharmaceutical Design The Roles of Chromatin Remodeling Proteins in Cancer
Current Protein & Peptide Science The Role of Statins for the Primary and Secondary Prevention of Coronary Heart Disease in Women
Current Pharmaceutical Design Coated with Nanomaterials Intraocular Lenses, Ophthalmic and Human Body Implantable Devices with High Catalytic Antioxidant Activities: A New Nanotechnology Strategy of Peroxidase Cellular Enzyme Mimics Increasing the Biocompatibility and Therapeutic Deployment of the Medical Prosthetic Device
Recent Patents on Drug Delivery & Formulation Insight View on Possible Role of Fluoroquinolones in Cancer Therapy
Current Topics in Medicinal Chemistry Treating Cancer and No-Cancer Pain in Older and Oldest Old Patients
Current Pharmaceutical Design Hyponatraemia: An Audit of Aged Psychiatry Patients Taking SSRIs and SNRIs
Current Drug Safety The Diagnosis of Drug-Induced Liver Disease
Current Clinical Pharmacology Safety Profile of Oral Iron Chelator Deferiprone in Chinese Children with Transfusion-Dependent Thalassaemia
Current Drug Safety